Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 345

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 345
---
 without knowing it. If left unchecked, these mutations could profoundly impact their health, affect family members, or alter their responses to treatments. Recognizing the importance of understanding one’s genetic makeup, we envision a future where genetic sequencing is integral to healthcare, beginning at birth and throughout the various stages of life. To achieve our vision, we have developed a suite of personalized medicine services that currently cover the following categories: • Wellness & Prevention: preventative health solutions that integrate genetic, microbiome and lifestyle data, enabling individuals to understand how their unique genes and habits impact their long -termhealth. These solutions also provide actionable prevention recommendations, and will be supported by nutrigenetic specialists who will help craft personalized preventive health strategies tailored to each individual’s specific needs; and • Diagnostics, Prognosis & Monitoring: precise clinical genetic services integrated with clinical data to enable accurate diagnostics and informed treatment decisions, covering the fields of oncology, prenatal care, rare diseases and human microbiome. Our portfolio aims to empower individuals to understand and make decisions based on their genetic results. We achieve this by possessing a unique scientific know -howthat allows us to sequence biological samples in -houseand a R&D division that continuously works to develop innovative genomic services, and potentially integrate the omni -modaldata with complex analytics to accelerate our innovation. To deliver our services, we process blood, tissue, microbiome and saliva samples from our own sales channels and partners. According to a Research and Markets report dated January23, 2025, a significant increase in interest in genetics among both consumers and healthcare professionals is expected, as the market adoption of genetic tests has experienced significant growth globally, driven by increased emphasis on early disease detection, personalized medicine, and genetics in addressing health conditions. A Horizon Grand View Research industry report from 2023 estimates that the Latin American genomics market will be valued at approximately $6.15 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.3% per year. This growth reflects the rising prevalence of genetic and rare disorders and the expanding use of genetic testing in fields such as oncology, where personalized approaches are increasingly critical. Additionally, these reports highlight that consumer demand for genetic testing continues to rise, further expanding the market and indicating a growing awareness of and interest in genetic health insights among the public. Advances in sequencing technology and rising awareness and demand for genetic testing support this growth. Further, according [a report published by the National Human Genome Research Institute in November 175 2021, technological